Doctor’s Passport

Find your next topic

Explore the current textbook

Available drafts · Clinical review pending
Membership
Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.
Full textbook

Indications for colectomy and proctocolectomy

Decide when ulcerative colitis requires emergency subtotal colectomy or elective removal of colon and rectum, match operative extent to acute physiology, dysplasia and chronic disease burden, and make ileal pouch versus permanent ileostomy a shared staged decision.

Saved on this device
!
Complicated or medically failing acute severe colitis

Perforation, toxic megacolon, severe haemorrhage, peritonism or physiological deterioration requires urgent colectomy; absence of response within seven days of infliximab or ciclosporin rescue is another indication for subtotal colectomy and ileostomy.

Action: Resuscitate and involve senior colorectal, gastroenterology, anaesthetic, critical-care and stoma teams. Stop prolonging failed rescue, cross-match blood, correct major electrolyte and fluid deficits, give sepsis antibiotics when indicated, and proceed to subtotal colectomy with end ileostomy and a safely managed retained rectum rather than constructing a pouch during the acute illness.

Open the sections you need. The overview is shown first.
01Core principlesThe concepts and mechanisms needed to understand the subject.

Colectomy decisions arise from four distinct problems. Acute danger demands source control. Chronic inflammation may remain unacceptable despite optimised therapy. Dysplasia or cancer may make organ preservation oncologically unsafe. Finally, medicine toxicity or an unmanageable surveillance burden may make surgery the better long-term option. The indication should be named explicitly because it determines timing, operative extent and whether delay for nutrition or steroid reduction is safe.

Emergency surgery for acute severe ulcerative colitis is staged: subtotal colectomy removes the inflamed colon, creates an end ileostomy and leaves a managed rectal stump. This controls systemic disease without adding a high-risk pelvic dissection or pouch anastomosis. After recovery, choices include completion proctectomy with permanent end ileostomy, restorative proctocolectomy with IPAA, or temporary retention of the rectum. Each remaining organ brings its own follow-up obligations.

Key points

  • Emergency indications include perforation, toxic megacolon, severe haemorrhage, uncontrolled sepsis and acute severe colitis that fails time-limited medical rescue.
  • The acute operation is subtotal colectomy with end ileostomy and preservation of the rectum; avoid ileal pouch construction in active severe colitis and corticosteroid exposure.
  • Elective proctocolectomy is considered for chronic active disease despite optimised therapy, intolerable treatment effects, cancer, unresectable or high-risk dysplasia and surveillance that cannot be performed effectively.
  • Ileal pouch-anal anastomosis and end ileostomy can provide equivalent overall quality of life; explain bowel frequency, continence, pouchitis, pelvic function, fertility, stoma care and reoperation.
  • A retained rectum or rectal stump continues to carry inflammation, bleeding and neoplasia risk and needs a documented treatment and surveillance plan.
  • Early stoma counselling and peer support improve preparation; present colectomy as effective treatment of colitis rather than as punishment for failed medicine.
02Mechanisms and patternsImportant relationships and how to distinguish them.
Immediate life threat

Perforation, toxic dilatation, uncontrolled haemorrhage and worsening shock are anatomical or physiological failures that cannot be repaired by further immune suppression.

Time-limited medical failure

ASUC without adequate response to corticosteroid and selected rescue by the guideline checkpoint needs surgery before anaemia and depletion deepen.

Chronic refractory disease

Persistent bleeding, urgency, nocturnal stool, steroid dependence or hospitalisation despite optimised therapy can make elective surgery the durable treatment.

Neoplasia indication

Colitis-associated cancer, non-endoscopically resectable dysplasia or high-risk multifocal or invisible dysplasia may require removal of at-risk colon and rectum.

Patient-defined treatment burden

Medicine adverse effects, repeated rescue, surveillance feasibility, continence priorities, fertility and willingness to manage a stoma or pouch shape the elective choice.

Red flags requiring action

  • Free gas, generalised guarding, shock or rising lactate indicates perforation or ischaemia and requires immediate source control.
  • Transfusion-dependent colorectal haemorrhage that continues despite resuscitation is an operative indication even without radiological megacolon.
  • Increasing dilatation, pain or organ dysfunction during ASUC overrides the intended day-three or day-seven assessment schedule.
  • Failure to improve after seven days of correctly selected infliximab or ciclosporin rescue should lead to subtotal colectomy rather than serial unproven rescue switches.
03Interpreting evidenceInformation, measurements and their limitations.
Reasoning sequence

Consider the information, its meaning and its limitations before deciding what follows.

  1. 01
    Daily ASUC response assessment
    Why
    link stool frequency, bleeding, CRP, abdomen and physiology to the rescue or colectomy clock.
    Interpretation and limitations
    Persistent high burden at day three starts definitive escalation; deterioration at any time or failed rescue by day seven moves to surgery.
  2. 02
    Cross-sectional and plain imaging
    Why
    detect dilatation, perforation, obstruction or collection and map anatomy before urgent intervention.
    Interpretation and limitations
    Free gas or worsening megacolon accelerates surgery; imaging should not delay laparotomy in unstable generalised peritonitis.
  3. 03
    High-quality surveillance colonoscopy and pathology review
    Why
    determine whether dysplasia is visible, resectable, multifocal, invisible or associated with cancer.
    Interpretation and limitations
    IBD-expert endoscopy and gastrointestinal pathology review prevent colectomy for an artefact while identifying lesions unsafe for endoscopic management.
  4. 04
    Nutritional, steroid and physiological assessment
    Why
    identify modifiable operative risk before elective or staged pelvic surgery.
    Interpretation and limitations
    Weight loss, anaemia and corticosteroid burden favour optimisation when safe; acute perforation removes the option to delay source control.
  5. 05
    Pelvic function and reproductive discussion
    Why
    establish continence, urinary, sexual and fertility priorities before choosing pouch or end ileostomy.
    Interpretation and limitations
    Baseline dysfunction and individual goals may favour permanent ileostomy or alter timing, and should be documented before consent.
04Applied reasoningWorked examples connecting principles to decisions.
01Worked case: rescue-refractory acute severe colitisUse the predefined endpoint and verify operative controlA 44-year-old with ASUC fails three days of hydrocortisone and receives ciclosporin rescue after joint review. Seven days later they still pass nine bloody stools daily, CRP is 96 mg/L, albumin 23 g/L and the abdomen is increasingly tender without free gas.
  1. 1Confirm correct steroid and rescue delivery, exclude untreated infection and repeat imaging and examination; worsening tenderness and absent response show that continuing ciclosporin will not restore a safe colon.
  2. 2Explain the indication, likely end ileostomy and retained rectal stump with the patient and stoma nurse, while resuscitating, cross-matching blood and arranging senior anaesthetic assessment.
  3. 3Proceed to subtotal colectomy and end ileostomy without constructing a pouch during acute inflammation, hypoalbuminaemia and recent high-dose corticosteroid exposure.
  4. 4Pathology shows continuous severe ulcerative colitis with deep ulceration, no Crohn features and no dysplasia; postoperative CRP falls to 28 mg/L and oral intake resumes on day four.
  5. 5Verify stoma independence, steroid-taper ownership and rectal-stump treatment, then schedule a recovery-stage discussion of completion proctectomy, IPAA or continued rectal retention.
02Multifocal invisible dysplasiaTurn expert pathology confirmation into an oncological operationA 52-year-old with 24 years of extensive colitis has high-grade dysplasia found in non-targeted biopsies from two separate colonic segments. Repeat high-definition chromoendoscopy by an IBD expert finds no resectable lesion, and two gastrointestinal pathologists confirm the diagnosis.
  1. 1Review scope quality, inflammation, biopsy map and pathology at the IBD dysplasia MDT so that an invisible multifocal finding is real and not an inadequately sampled inflamed colon.
  2. 2Explain the field risk and limitations of continued endoscopic surveillance, including the possibility of synchronous occult carcinoma despite no visible lesion.
  3. 3Discuss restorative proctocolectomy with IPAA against total proctocolectomy with end ileostomy, covering continence, frequency, pouchitis, pelvic nerve effects, fertility and stoma outcomes.
  4. 4The patient chooses elective proctocolectomy with IPAA in a high-volume unit; final pathology confirms multifocal high-grade dysplasia and no invasive cancer, with clear margins.
  5. 5Verify postoperative pouch function, defunctioning-ileostomy plan and retained anal-transition-zone surveillance rather than declaring neoplasia follow-up complete.
03Chronic steroid-dependent colitisOffer elective surgery before another emergency admissionA 35-year-old with extensive ulcerative colitis has four admissions in 18 months, cannot reduce prednisolone below 20 mg without bleeding and urgency, and has failed two appropriate advanced therapies. There is no dysplasia or acute severe attack today.
  1. 1Confirm objective active disease and that adherence, infection, dose optimisation and reasonable medical options have been reviewed; quantify the effect on work, sleep, nutrition and treatment toxicity.
  2. 2Arrange elective colorectal and stoma consultations rather than reserving surgery for a future perforation, and obtain nutrition, anaemia, bone, thrombotic and steroid-risk assessment.
  3. 3Compare IPAA, end ileostomy and staged approaches with the patient’s baseline continence, fertility plans and willingness to accept repeated pouch or stoma care.
  4. 4After nutrition support and reduction to the lowest safe steroid dose, the patient chooses staged restorative proctocolectomy; the first planned operation proceeds without emergency physiology.
  5. 5Verify pathology, complications, steroid taper and patient-reported bowel and pelvic function at each stage, retaining the option to revise the reconstruction plan if recovery is poor.
05Checking understandingVerify the reasoning, revisit uncertainties and apply feedback.
  • During acute medical treatment record the agreed day-three and day-seven decision points, named rescue drug and exact complication thresholds for earlier surgery.
  • After subtotal colectomy monitor sepsis resolution, ileostomy output, fluid and renal function, wound, venous thrombosis and retained rectal-stump discharge or bleeding.
  • Before later pelvic surgery confirm nutrition, anaemia, steroid dose, infection status, fertility discussion, continence and the patient’s updated preference after living with an ileostomy.
  • After IPAA track stool frequency, nocturnal leakage, urgency, pouchitis, cuffitis, sexual and urinary function; after end ileostomy track appliance fit, skin, hernia, output and hydration.
  • Continue neoplasia surveillance for any retained rectum, cuff, anal transition zone or pouch according to pathology and individual risk rather than assuming colectomy removes every risk.
06Special situationsVariants, exceptions and circumstances that change the usual approach.

Acute surgery is staged

Subtotal colectomy controls colonic disease while avoiding a difficult pelvic anastomosis during severe inflammation and physiological depletion.

Rescue has an endpoint

Infliximab or ciclosporin is not permission for indefinite observation; failure by seven days is a guideline indication for colectomy.

Quality of life is comparable

Population outcomes can be similar after IPAA and end ileostomy, so individual function and preferences should drive reconstruction.

Dysplasia needs expert confirmation

IBD endoscopy and gastrointestinal pathology review separate resectable visible lesions from high-risk invisible or multifocal disease.

A retained rectum remains diseased tissue

Stump inflammation, bleeding and neoplasia remain possible until completion proctectomy and require explicit ownership.

07Common pitfallsFrequent interpretation and management errors.
  1. 01

    Presenting colectomy only after shock develops denies patients time for stoma counselling and increases the physiological price of surgery.

  2. 02

    Constructing an ileal pouch during fulminant colitis and high-dose steroid exposure adds avoidable pelvic leak and sepsis risk.

  3. 03

    Calling one unconfirmed dysplasia biopsy an automatic proctocolectomy indication skips expert endoscopic and pathology review.

  4. 04

    Assuming every medically refractory patient wants a pouch ignores permanent ileostomy quality of life and individual continence or fertility priorities.

  5. 05

    Discharging after subtotal colectomy without rectal-stump and steroid plans creates preventable inflammation, adrenal and surveillance harm.

Practice

Two practice questions

Question 1 of 20 correct
Colorectal surgeryOriginal SBA

Operation for failed acute rescue

A patient with ASUC has not responded within seven days of correctly delivered infliximab rescue and remains physiologically depleted with frequent bloody stools. There is no established perforation. Which operation does current BSG guidance support?

Sources and review status3 sources · checked 8 Sept 2026 · clinical review pending
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Apply principles in context and verify current guidance when a decision affects care. Source check completed 8 Sept 2026; clinical approval remains outstanding.

Authoring stateComplete draftClinical stateAwaiting reviewJurisdictionUnited Kingdom